title: Red cell ferritin, a marker of iron deficiency in hemodialysis patients.
abstract: Estimation of red cell ferritin (RCFer) may give a good indication of iron supply to the erythron and it may therefore be clinically useful for the detection of functional iron deficiency. In a cross-sectional study of hemodialysis patients on erythropoietin (EPO) therapy and regular oral iron we have compared the RCFer levels with conventional indicators of iron status. The patients studied, 19 female, 48 male, mean age 62 +/- 3.6 years (range 20-83 years) were characterized by the following mean parameters: aluminum 1.24 +/- 0.12 mumol/L, PTH 115.7 +/- 39 pg/mL, vitamin B12 626 +/- 71.2 ng/L, serum folate 18.8 +/- 2.2 micrograms/L, and hemoglobin 9.8 +/- 0.3 g/dL (range 7.3-12.4). The median serum ferritin (SF), RCFer, total iron binding capacity (TIBC), transferrin saturation (TS), and serum iron were 68 micrograms/L, 14.1 ag ferritin/red cell, 57 mumol/L, 20% and 11.5 mumol/L, respectively. Eleven patients had a reduced RCFer (< 7 ag ferritin/red cell), 5 had a SF of < 15 micrograms/L and 22 a TS of < 16%. The occurrence of functional iron deficiency was suggested by the presence of 10 subjects with reduced RCFer despite normal SF levels (15-240 micrograms/L). Four patients with reduced SF showed acceptable levels of RCFer, suggesting that some patients may maintain an adequate iron supply despite diminished iron stores. Despite oral iron therapy, a significant number of patients (63%) on regular hemodialysis remain relatively iron deficient with a serum ferritin of less than 100 micrograms/L. It has previously been proposed that oral iron provides adequate supplementation during increased demand caused by EPO stimulation. The present study has demonstrated overt iron deficiency in five subjects and suggests functional iron deficiency in a further seven (22% of total patients). We therefore conclude that oral iron therapy cannot maximize the response to EPO.
authors.affiliation: Renal Unit, Leeds General Infirmary, United Kingdom.
authors.forename: S
authors.initials: S
authors.lastname: Bhandari
authors.forename: A K
authors.initials: AK
authors.lastname: Owda
authors.forename: R G
authors.initials: RG
authors.lastname: Kendall
authors.forename: N
authors.initials: N
authors.lastname: Moran
authors.forename: D R
authors.initials: DR
authors.lastname: Norfolk
authors.forename: A M
authors.initials: AM
authors.lastname: Brownjohn
authors.forename: J H
authors.initials: JH
authors.lastname: Turney
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000535:Aluminum / Q000097:blood; D000747:Anemia, Hypochromic / Q000097:blood / Q000209:etiology; D015415:Biomarkers / Q000097:blood*; D003430:Cross-Sectional Studies; D004912:Erythrocytes / Q000737:chemistry*; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood*; D005492:Folic Acid / Q000097:blood; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000008:administration & dosage; D000090463:Iron Deficiencies; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D015415:Biomarkers; D006454:Hemoglobins; D004921:Erythropoietin; D005293:Ferritins; D005492:Folic Acid; D000535:Aluminum; D007501:Iron; D014805:Vitamin B 12